期刊
CEPHALALGIA
卷 23, 期 3, 页码 183-185出版社
SAGE PUBLICATIONS LTD
DOI: 10.1046/j.1468-2982.2003.00496.x
关键词
migraine; treatment of the migraine attack; substance-P antagonist
A global, double-blind, randomized, placebo-controlled, dose-finding, parallel-group trial was conducted to compare three oral doses of RPR100893 (1, 5, 20 mg), a substance-P antagonist, and placebo in 139 patients with migraine attacks with moderate or severe headache intensity. Headache intensity and improvement of headache after 2 h were not different in the four treatment groups. Therefore, it is concluded that this oral substance-P antagonist in the doses used here is not effective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据